173 related articles for article (PubMed ID: 31176433)
1. MRI Radiomic Analysis of IMRT-Induced Bladder Wall Changes in Prostate Cancer Patients: A Relationship with Radiation Dose and Toxicity.
Abdollahi H; Tanha K; Mofid B; Razzaghdoust A; Saadipoor A; Khalafi L; Bakhshandeh M; Mahdavi SR
J Med Imaging Radiat Sci; 2019 Jun; 50(2):252-260. PubMed ID: 31176433
[TBL] [Abstract][Full Text] [Related]
2. Rectal wall MRI radiomics in prostate cancer patients: prediction of and correlation with early rectal toxicity.
Abdollahi H; Mahdavi SR; Mofid B; Bakhshandeh M; Razzaghdoust A; Saadipoor A; Tanha K
Int J Radiat Biol; 2018 Sep; 94(9):829-837. PubMed ID: 29969358
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging radiomic feature analysis of radiation-induced femoral head changes in prostate cancer radiotherapy.
Abdollahi H; Mahdavi SR; Shiri I; Mofid B; Bakhshandeh M; Rahmani K
J Cancer Res Ther; 2019 Mar; 15(Supplement):S11-S19. PubMed ID: 30900614
[TBL] [Abstract][Full Text] [Related]
4. Machine learning-based radiomic models to predict intensity-modulated radiation therapy response, Gleason score and stage in prostate cancer.
Abdollahi H; Mofid B; Shiri I; Razzaghdoust A; Saadipoor A; Mahdavi A; Galandooz HM; Mahdavi SR
Radiol Med; 2019 Jun; 124(6):555-567. PubMed ID: 30607868
[TBL] [Abstract][Full Text] [Related]
5. CT imaging markers to improve radiation toxicity prediction in prostate cancer radiotherapy by stacking regression algorithm.
Mostafaei S; Abdollahi H; Kazempour Dehkordi S; Shiri I; Razzaghdoust A; Zoljalali Moghaddam SH; Saadipoor A; Koosha F; Cheraghi S; Mahdavi SR
Radiol Med; 2020 Jan; 125(1):87-97. PubMed ID: 31552555
[TBL] [Abstract][Full Text] [Related]
6. Serial T2-Weighted Magnetic Resonance Images Acquired on a 1.5 Tesla Magnetic Resonance Linear Accelerator Reveal Radiomic Feature Variation in Organs at Risk: An Exploratory Analysis of Novel Metrics of Tissue Response in Prostate Cancer.
Lorenz JW; Schott D; Rein L; Mostafaei F; Noid G; Lawton C; Bedi M; Li XA; Schultz CJ; Paulson E; Hall WA
Cureus; 2019 Apr; 11(4):e4510. PubMed ID: 31259119
[TBL] [Abstract][Full Text] [Related]
7. Voxel-Based Analysis for Identification of Urethrovesical Subregions Predicting Urinary Toxicity After Prostate Cancer Radiation Therapy.
Mylona E; Acosta O; Lizee T; Lafond C; Crehange G; Magné N; Chiavassa S; Supiot S; Ospina Arango JD; Campillo-Gimenez B; Castelli J; de Crevoisier R
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):343-354. PubMed ID: 30716523
[TBL] [Abstract][Full Text] [Related]
8. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer.
Zapatero A; Roch M; Büchser D; Castro P; Fernández-Banda L; Pozo G; Liñán O; Martin de Vidales C; Cruz-Conde A; García-Vicente F
Clin Transl Oncol; 2017 Sep; 19(9):1161-1167. PubMed ID: 28374321
[TBL] [Abstract][Full Text] [Related]
9. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
[TBL] [Abstract][Full Text] [Related]
10. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
Vesprini D; Sia M; Lockwood G; Moseley D; Rosewall T; Bayley A; Bristow R; Chung P; Ménard C; Milosevic M; Warde P; Catton C
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e415-21. PubMed ID: 21477939
[TBL] [Abstract][Full Text] [Related]
11. Radiomics based predictive modeling of rectal toxicity in prostate cancer patients undergoing radiotherapy: CT and MRI comparison.
Hassaninejad H; Abdollahi H; Abedi I; Amouheidari A; Tavakoli MB
Phys Eng Sci Med; 2023 Dec; 46(4):1353-1363. PubMed ID: 37556091
[TBL] [Abstract][Full Text] [Related]
12. Impact of changing rectal dose volume parameters over time on late rectal and urinary toxicity after high-dose intensity-modulated radiotherapy for prostate cancer: A 10-years single centre experience.
Fonteyne V; Sadeghi S; Ost P; Vanpachtenbeke F; Vuye P; Lumen N; De Meerleer G
Acta Oncol; 2015 Jun; 54(6):854-61. PubMed ID: 25387271
[TBL] [Abstract][Full Text] [Related]
13. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
[TBL] [Abstract][Full Text] [Related]
14. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy.
Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R
Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192
[TBL] [Abstract][Full Text] [Related]
15. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
[TBL] [Abstract][Full Text] [Related]
16. Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: Impact on acute urinary toxicity and health-related quality of life.
Sanmamed N; Chung P; Berlin A; Adleman J; Borg J; Lao B; Ghai S; Weersink R; Simeonov A; Rink A; Menard C; Helou J
Brachytherapy; 2019; 18(4):477-483. PubMed ID: 31109872
[TBL] [Abstract][Full Text] [Related]
17. Intensity modulated proton and photon therapy for early prostate cancer with or without transperineal injection of a polyethylen glycol spacer: a treatment planning comparison study.
Weber DC; Zilli T; Vallee JP; Rouzaud M; Miralbell R; Cozzi L
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e311-8. PubMed ID: 22999271
[TBL] [Abstract][Full Text] [Related]
18. MRI-based radiomics signature for localized prostate cancer: a new clinical tool for cancer aggressiveness prediction? Sub-study of prospective phase II trial on ultra-hypofractionated radiotherapy (AIRC IG-13218).
Gugliandolo SG; Pepa M; Isaksson LJ; Marvaso G; Raimondi S; Botta F; Gandini S; Ciardo D; Volpe S; Riva G; Rojas DP; Zerini D; Pricolo P; Alessi S; Petralia G; Summers PE; Mistretta FA; Luzzago S; Cattani F; De Cobelli O; Cassano E; Cremonesi M; Bellomi M; Orecchia R; Jereczek-Fossa BA
Eur Radiol; 2021 Feb; 31(2):716-728. PubMed ID: 32852590
[TBL] [Abstract][Full Text] [Related]
19. Intensity-modulated radiation therapy from 70Gy to 80Gy in prostate cancer: six- year outcomes and predictors of late toxicity.
Jolnerovski M; Salleron J; Beckendorf V; Peiffert D; Baumann AS; Bernier V; Huger S; Marchesi V; Chira C
Radiat Oncol; 2017 Jun; 12(1):99. PubMed ID: 28622770
[TBL] [Abstract][Full Text] [Related]
20. Changes in ADC and T2-weighted MRI-derived radiomic features in patients treated with focal salvage HDR prostate brachytherapy for local recurrence after previous external-beam radiotherapy.
Lee SL; Ravi A; Morton G; Loblaw A; Tseng CL; Haider M; Murgic J; Nicolae A; Semple M; Chung HT
Brachytherapy; 2019; 18(5):567-573. PubMed ID: 31126856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
